

# Regulatory withdrawal of medicines marketed with unapproved case study

Journal of Pharmaceutical Policy and Practice

8, 25

DOI: [10.1186/s40545-015-0046-2](https://doi.org/10.1186/s40545-015-0046-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 13.	1.1	17
2	Role of Payers in the Development of Cardiovascular Therapeutics. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2822-2830.	1.2	5
3	Engineering Antibodies. <i>Journal of the Indian Institute of Science</i> , 2018, 98, 5-20.	0.9	1
4	The Australian Managed Entry Scheme: Are We Getting it Right?. <i>Pharmacoeconomics</i> , 2018, 36, 555-565.	1.7	17
6	An ethical framework for the creation, governance and evaluation of accelerated access programs. <i>Health Policy</i> , 2018, 122, 984-990.	1.4	10
7	Access to High-Cost Medicines in Australia. , 2018, , 165-181.		1
8	Population-Based Outcomes in NSCLC. <i>JNCI Cancer Spectrum</i> , 2019, 3, plz022.	1.4	0
9	Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency. <i>Milbank Quarterly</i> , 2019, 97, 820-857.	2.1	28
10	A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. <i>ELife</i> , 2019, 8, .	2.8	71
11	Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. <i>Clinical Drug Investigation</i> , 2019, 39, 595-606.	1.1	6
12	Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study. <i>Oncology</i> , 2019, 97, 1-6.	0.9	12
13	Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 365-372.	0.4	18
14	Formulating an Ethics of Pharmaceutical Disinvestment. <i>Journal of Bioethical Inquiry</i> , 2020, 17, 75-86.	0.9	4
15	FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis. <i>Cancers</i> , 2020, 12, 437.	1.7	19
16	Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 424-426.	1.4	4
17	Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways. <i>Clinical and Translational Science</i> , 2020, 13, 451-461.	1.5	16
18	A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 175-186.	0.7	21
19	Physicians' attitudes towards accelerated access to medicines. <i>Health Economics, Policy and Law</i> , 2021, 16, 154-169.	1.1	6

#	ARTICLE	IF	CITATIONS
20	Consumer perspectives of accelerated access to medicines: a qualitative study. <i>Journal of Health Organization and Management</i> , 2021, 35, 987-1007.	0.6	4
21	A Middle Ground for Accelerated Drug Approval—Lessons From Aducanumab. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1367-1368.	3.8	10
22	Accelerating regulatory approval of anticancer therapies: Benefits, drawbacks and recommendations for a more sustainable approach. <i>Journal of Cancer Policy</i> , 2021, 29, 100296.	0.6	1
23	Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1307-1313.	0.9	3
24	Public Participation in Access to Medicines. , 2020, , 261-291.		1
25	The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada. <i>Healthcare Policy</i> , 2022, 17, 81-90.	0.3	0
26	In Silico Prediction Model of STAT3 Inhibition and in Vivo Antitumor Activity of Cucurbitacin IIb and Kinoin a from <i>Ibervillea Sonorae</i> . <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
27	Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	8
28	The Host Stroma and the Tumour Microenvironment. , 2023, , 93-110.		0
29	Media coverage of cancer therapeutics: A review of literature. <i>Journal of Cancer Policy</i> , 2023, 36, 100418.	0.6	2